Paragon 28 Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $13.425
- Today's High:
- $13.83
- Open Price:
- $13.47
- 52W Low:
- $12.45
- 52W High:
- $21.49
- Prev. Close:
- $13.5
- Volume:
- 299734
Company Statistics
- Market Cap.:
- $1.22 billion
- Book Value:
- 2.412
- Revenue TTM:
- $200.56 million
- Operating Margin TTM:
- -16.89%
- Gross Profit TTM:
- $148.93 million
- Profit Margin:
- -34.12%
- Return on Assets TTM:
- -7.48%
- Return on Equity TTM:
- -36.41%
Company Profile
Paragon 28 Inc had its IPO on 2021-10-15 under the ticker symbol FNA.
The company operates in the Healthcare sector and Medical Devices industry. Paragon 28 Inc has a staff strength of 463 employees.
Stock update
Shares of Paragon 28 Inc opened at $13.47 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $13.43 - $13.83, and closed at $13.72.
This is a +1.63% increase from the previous day's closing price.
A total volume of 299,734 shares were traded at the close of the day’s session.
In the last one week, shares of Paragon 28 Inc have slipped by -7.36%.
Paragon 28 Inc's Key Ratios
Paragon 28 Inc has a market cap of $1.22 billion, indicating a price to book ratio of 9.1946 and a price to sales ratio of 8.9434.
In the last 12-months Paragon 28 Inc’s revenue was $200.56 million with a gross profit of $148.93 million and an EBITDA of $-20295000. The EBITDA ratio measures Paragon 28 Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Paragon 28 Inc’s operating margin was -16.89% while its return on assets stood at -7.48% with a return of equity of -36.41%.
In Q2, Paragon 28 Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 20%.
Paragon 28 Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.9 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Paragon 28 Inc’s profitability.
Paragon 28 Inc stock is trading at a EV to sales ratio of 9.0507 and a EV to EBITDA ratio of -85.5987. Its price to sales ratio in the trailing 12-months stood at 8.9434.
Paragon 28 Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $300.84 million
- Total Liabilities
- $56.44 million
- Operating Cash Flow
- $-15263000.00
- Capital Expenditure
- $8.12 million
- Dividend Payout Ratio
- 0%
Paragon 28 Inc ended 2024 with $300.84 million in total assets and $0 in total liabilities. Its intangible assets were valued at $300.84 million while shareholder equity stood at $199.04 million.
Paragon 28 Inc ended 2024 with $0 in deferred long-term liabilities, $56.44 million in other current liabilities, 824000.00 in common stock, $-87739000.00 in retained earnings and $25.47 million in goodwill. Its cash balance stood at $56.75 million and cash and short-term investments were $56.75 million. The company’s total short-term debt was $652,000 while long-term debt stood at $42.26 million.
Paragon 28 Inc’s total current assets stands at $180.43 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $35.20 million compared to accounts payable of $29.68 million and inventory worth $85.23 million.
In 2024, Paragon 28 Inc's operating cash flow was $-15263000.00 while its capital expenditure stood at $8.12 million.
Comparatively, Paragon 28 Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $13.72
- 52-Week High
- $21.49
- 52-Week Low
- $12.45
- Analyst Target Price
- $27.29
Paragon 28 Inc stock is currently trading at $13.72 per share. It touched a 52-week high of $21.49 and a 52-week low of $21.49. Analysts tracking the stock have a 12-month average target price of $27.29.
Its 50-day moving average was $15.62 and 200-day moving average was $17.59 The short ratio stood at 4.37 indicating a short percent outstanding of 0%.
Around 4216.8% of the company’s stock are held by insiders while 4514.4% are held by institutions.
Frequently Asked Questions About Paragon 28 Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.